The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium.
OBJECTIVE
To assess the potential of ziprasidone to alter the renal clearance and steady-state serum levels of lithium.


METHODS
Healthy subjects who had stable serum lithium levels during the first 7 days of treatment with lithium 900 mg day(-1), given as two divided daily doses, were randomized to receive concomitant treatment with either ziprasidone, 40 mg day(-1), given as two divided daily doses, on days 9-11 followed by 80 mg day(-1), given as two divided daily doses on days 12-15 (n = 12), or placebo twice daily (n = 13). Ziprasidone or placebo was administered 2 h before each dose of lithium.


RESULTS
Ziprasidone administration was associated with a 0.07 mmol l(-1) (13%) mean increase in steady-state serum lithium levels compared with a mean increase of 0.06 mmol l(-1) (10%) with placebo. Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group. None of these differences between the two groups was statistically or clinically significant.


CONCLUSIONS
Ziprasidone does not alter steady-state serum lithium concentrations or renal clearance of lithium.
Apseloff
G
G
Department of Pharmacology, Ohio State University, Columbus, OH, USA.
Mullet
D
D
Wilner
K D
KD
Anziano
R J
RJ
Tensfeldt
T G
TG
Pelletier
S M
SM
Gerber
N
N
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D008094:Lithium / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D008094:Lithium